Artiva Biotherapeutics — Q3 2026 Earnings Summary

Artiva Biotherapeutics has discontinued the development of its AlloNK (AB-101) therapy for autoimmune diseases following updated clinical data showing insufficient durability of clinical response and the occurrence of two Grade 5 safety events. One fatal event was assessed as likely related to fludarabine-associated neurotoxicity, while a second sudden death was deemed unrelated to the study treatment. In response to these findings, the company is reducing its workforce by approximately 94% and engaging Leerink Partners to evaluate strategic alternatives, which may include a merger, asset sale, or liquidation. As of September 30, 2026, the company reported approximately $319.1 million in cash, cash equivalents, and investments.